GSK Receives U.S. FDA Approval for Expanded Use of RSV Vaccine

GSK Receives U.S. FDA Approval for Expanded Use of RSV Vaccine: GSK has received approval from the U.S. Food and Drug Administration for expanded use of its vaccine targeting Respiratory Syncytial Virus (RSV), a respiratory infection that can cause serious illness in older adults and vulnerable populations. The regulatory decision allows broader use of the vaccine, marking an important step in efforts to strengthen protection against RSV in the United States. Expanded protection against RSV, a common respiratory virus that can lead to severe lung infections, particularly among older adults and people with underlying health conditions. Public health experts say improved vaccination coverage could help reduce hospitalizations during peak respiratory illness seasons. The expanded approval enables healthcare providers to offer the vaccine to a wider group of eligible adults, increasing prevention options for patients at higher risk of complications. Growing Focus on Adult Vaccination Health authorities and pharmaceutical companies are placing greater emphasis on vaccines for respiratory diseases that affect adults, including RSV, influenza, and COVID‑19. Industry analysts say the expanded approval for the RSV vaccine reflects growing investment in preventive healthcare strategies within the global healthcare industry. Role of GSK in Vaccine Development GSK is one of the world's leading vaccine manufacturers and has long been involved in the development of vaccines targeting infectious diseases. The company continues to invest in medical research and vaccine innovation aimed at improving prevention strategies for respiratory infections and other major health threats. Healthcare experts say the expanded approval could support wider vaccination efforts and help reduce the public health burden of RSV in the coming years.